Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says
Executive Summary
Roche expects to resolve a shortage of Cytovene I.V. by the second quarter
You may also be interested in...
Roche Cytovene I.V. shortage lengthens
Roche expects "intermittent complete out-of-stock situations" for Cytovene I.V. to continue until the middle of the second quarter. "Despite the implementation of a system to manage the available stock, demand exceeds our ability to supply" ganciclovir, a Feb. 6 "Dear Doctor" letter says. Roche had expected to resolve the shortage of the CMV retinitis product by the second quarter (1"The Pink Sheet" Jan. 14, p. 19)....
Roche Cytovene I.V. shortage lengthens
Roche expects "intermittent complete out-of-stock situations" for Cytovene I.V. to continue until the middle of the second quarter. "Despite the implementation of a system to manage the available stock, demand exceeds our ability to supply" ganciclovir, a Feb. 6 "Dear Doctor" letter says. Roche had expected to resolve the shortage of the CMV retinitis product by the second quarter (1"The Pink Sheet" Jan. 14, p. 19)....
Roche Valcyte Expected To Erode Ganciclovir Scripts After Spring Launch
Roche anticipates that Valcyte (valganciclovir) will begin to erode oral Cytovene (ganciclovir) prescriptions for the treatment of cytomegalovirus retinitis in AIDS patients following spring launch.